1. Medtech Insight

US Approvals Analysis: April A Big Month For Non-Invasive Neurostim

 
• By David Filmore

Two de novo go-aheads granted by FDA last month sent non-implantable neurostimulation devices to market, one for headaches and the other for tear production. Overall, the agency granted four de novos in April, continuing a strong trend this year for that marketing pathway, according to Medtech Insight's Approvals Tracker.

FDA approved background, 3D rendering, blue street sign

[Editors' note: For sortable and searchable tables of US and international approvals and clearances check out our Approvals Tracker.]

R&D into non-invasive neurostimulation devices, a market attracting serious attention and investment from both drug and device firms, showed signs...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Policy & Regulation